|
Diabetes Medication Article
Types of Insulin Delivery Devices
All insulin delivery devices inject insulin through the skin and into
the fatty tissue below.
Most people inject the insulin with a syringe that delivers insulin just
under the skin. Others use insulin pens, jet injectors, or insulin pumps.
Several new approaches for taking insulin are under development.
Syringes
Syringes are hypodermic needles attached to hollow barrels that people
with diabetes use to inject insulin. Insulin syringes are small with very
sharp points. Most have a special coating to help the needles enter the
skin as painlessly as possible. Insulin syringes come in several different
sizes to match insulin strength and dosage.
http://www.diabetestestingcenter.com
Byetta Drug News
Byetta Drug
NEW YORK -(Dow Jones)- After years of anticipation, a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), faces a crucial Food and Drug Administration approval decision this week. Called ...
Read moreAmylin, Lilly Diabetes Drug Faces Crucial FDA Decision - NASDAQ
On Friday, Amylin and partner Eli Lilly are expected to get a decision by the Food and Drug Administration on Byetta, its once-a-week treatment for Type II diabetes. We've been watching Alkermes, which supplies the technology that makes the drug last ...
Read moreDiabetes drug makers move before ruling - optionMONSTER
WE ARE INITIATING COVERAGE on Amylin Pharmaceuticals (ticker: AMLN) with a Buy rating and a price target of $26. We derived our price target by using a discounted-cash-flow analysis. Amylin has a Phase III drug, Byetta LAR, which would be the first ...
Read moreAiming High for Amylin Pharmaceuticals - Barron's Online
THURSDAY, Feb. 18 (HealthDay News) -- The U.S. Food and Drug Administration is defending its decision in late January to approve a new diabetes drug, Victoza (liraglutide), even though animal studies suggest it might increase the risk for a rare ...
Read moreFDA approved diabetes drug despite hints at cancer risk - WLOX
The first is the licensing of RP44, which Redpoint has disclosed in January 2010 to be rebaudioside C (Reb-C), a component of the Stevia plant. Redpoint has spent the last eight months securing the intellectual property around RP44, an all-natural ...
Read moreRedpoint Sitting in the Sweet Spot - Zacks.com
NEW YORK — Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes drugs from Eli Lilly and Co. In the deal, Transition Therapeutics is gaining products that are in preclinical ...
Read moreTransition Therapeutics will pay Lilly $1M upfront for preclinical ... - San Francisco Examiner
Drug developer Transition Therapeutics Inc. said today that it will pay $1 million to license a group of potential diabetes drugs from Indianapolis-based Eli Lilly and Co. In the deal, Transition Therapeutics is gaining products that are in ...
Read moreTransition Therapeutics, Indianapolis-based Eli Lilly in $1M diabetes ... - Indianapolis Star
... BMO analyst Jason Zhang anticipated Food and Drug Administration approval of Amylin’s exenatide LAR, a long-acting version of Amylin and Eli Lilly’s (LLY) diabetes treatment Byetta, could be delayed until mid or late 2011. Regulators are ...
Read more